リモナバン
リモナバン 物理性質
- 融点 :
- 154.7 °C
- 比重(密度) :
- 1.41±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- RT
- 溶解性:
- DMSO (最大 20mg/ml) またはエタノール (最大 20mg/ml) に可溶。
- 酸解離定数(Pka):
- 11.31±0.20(Predicted)
- 外見 :
- 個体
- 色:
- 白い
- 安定性：:
- 防湿。 -20°C の DMSO またはエタノール溶液で最大 3 か月間保存できます。
- CAS データベース:
- 168273-06-1(CAS DataBase Reference)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
リモナバン 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
リモナバン 化学特性,用途語,生産方法
効能
抗肥満薬, 禁煙補助薬, カンナビノイド受容体逆作動薬
説明
Rimonabant is a first-in-class drug launched as an oral treatment
for obesity, and its mechanism of action involves the selective antagonism
of cannabinoid type 1 (CB1) receptor. It is specifically indicated as an adjunct
to diet and exercise for the treatment of obese patients (body mass index
[BMI]≥30 kg/m
2), or overweight patients (BMI＞27 kg/m
2) with associated risk
factors such as type 2 diabetes or dyslipidemia. Additionally, rimonabant is
currently under development as a treatment for nicotine dependence. The CB1
and CB2 receptors, along with their endogenous ligands, constitute the endocannabinoid
system. The CB1 receptor is expressed in the brain, adipose tissue,
and several peripheral organs; the CB2 receptor is predominantly expressed in
immune cells. Activation of the CB1 receptor in the CNS is associated with
appetite stimulation and the modulation of brain reward mechanism, whereas
activation in the periphery favors metabolic processes that lead to hepatic lipogenesis
and impaired glucose homeostasis. Rimonabant acts by selectively
blocking the action of central and peripheral CB1 receptors, thereby reducing
food intake and improving lipid and glucose metabolism.
使用
Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane
リモナバン 上流と下流の製品情報
原材料
準備製品
リモナバン 生産企業
Global( 262)Suppliers
168273-06-1(リモナバン)キーワード:
- 168273-06-1
- ACOMPLIA
- RIMONABANT
- RIMONABANT(ACOMPLIA,SR141716)
- 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
- 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-
- 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide
- A 281
- Sr 141716
- Unii-rml78en3xe
- Rimonabant base ,99%
- N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-Methyl-1H-pyrazole-3-carboxyaMide
- RiMonabant (SR141716)
- N-piperidino-5-(4-chlorophenyl)-1(2,4-dichlorophenyl)-4-Methyl-pyrazole-3-carboxaMide
- N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride Rimonabant(SR141716A) 158681-13-1 (HCl CAS)
- Rimonabant base
- 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamid
- xibuqum
- Limonabant
- Rimonabant Powder
- rimobrant
- RimonabantQ: What is
Rimonabant Q: What is the CAS Number of
Rimonabant Q: What is the storage condition of
Rimonabant Q: What are the applications of
Rimonabant
- Rimonaban
- リモナバン
- リモナバント
- リモナバント (JAN)
- 5-(4-クロロフェニル)-1-(2,4-ジクロロフェニル)-4-メチル-N-(ピペリジン-1-イル)-1H-ピラゾール-3-カルボキサミド
- N-(ピペリジン-1-イル)-5-(4-クロロフェニル)-1-(2,4-ジクロロフェニル)-4-メチル-1H-ピラゾール-3-カルボアミド
- SR-141716
- N-(1-ピペリジニル)-1-(2,4-ジクロロフェニル)-4-メチル-5-(4-クロロフェニル)-1H-ピラゾール-3-カルボアミド
- N-ピペリジノ-1-(2,4-ジクロロフェニル)-4-メチル-5-(4-クロロフェニル)-1H-ピラゾール-3-カルボアミド